Comparing Prestige Consumer Healthcare (NYSE:PBH) & Chugai Pharmaceutical (OTCMKTS:CHGCY)

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) and Prestige Consumer Healthcare (NYSE:PBH – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Volatility and Risk

Chugai Pharmaceutical has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Institutional & Insider Ownership

0.0% of Chugai Pharmaceutical shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Chugai Pharmaceutical and Prestige Consumer Healthcare’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chugai Pharmaceutical 35.63% 24.91% 20.67%
Prestige Consumer Healthcare 13.29% 11.28% 5.25%

Analyst Ratings

This is a summary of current ratings and recommmendations for Chugai Pharmaceutical and Prestige Consumer Healthcare, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chugai Pharmaceutical 0 3 1 1 2.60
Prestige Consumer Healthcare 1 3 1 0 2.00

Prestige Consumer Healthcare has a consensus price target of $67.00, indicating a potential upside of 39.09%. Given Prestige Consumer Healthcare’s higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Chugai Pharmaceutical.

Earnings & Valuation

This table compares Chugai Pharmaceutical and Prestige Consumer Healthcare”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Chugai Pharmaceutical $8.41 billion 8.94 $2.91 billion $0.96 23.82
Prestige Consumer Healthcare $1.09 billion 2.10 $190.30 million $3.24 14.87

Chugai Pharmaceutical has higher revenue and earnings than Prestige Consumer Healthcare. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Summary

Chugai Pharmaceutical beats Prestige Consumer Healthcare on 10 of the 14 factors compared between the two stocks.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.

About Prestige Consumer Healthcare

(Get Free Report)

Prestige Consumer Healthcare, Inc. develops, markets and distributes over-the-counter health and personal-care products. Its portfolio includes brands such as Dramamine for motion sickness, Clear Eyes for eye care, Chloraseptic for sore-throat relief, Compound W for wart removal, and Summer’s Eve for feminine care. The company’s products serve categories including eye and ear care, cough and cold relief, pain relief, digestive health, and women’s health. They are sold through retail channels such as drugstores, supermarkets, mass-market retailers and online sellers.

Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.